Malignancy history had no marked effect on the prognosis of COVID-19: A cohort study

Abstract

Background Primary disease influenced the prognosis of coronavirus disease 2019 (COVID-19), but the clinical characters of patients accompanied with tumor were few reported. Methods We enrolled 528 COVID-19 patients. Date of laboratory tests and outcome were divided to corresponding groups to compare the risk factors of disease severity, progression and survival. Results The disease severity at hospitalization, progression rate (51.43% vs 54.42%) and mortality (19.51% vs 11.91%) were equal between tumor and non-tumor group. In both groups, lymphopenia was negatively related to the severity grading (OR = 0.019 and 0.168 separately), NLR was positively correlated with the poor outcome (OR = 1.371 and 1.155 separately), and CRP was relevant to the disease progression and survival (OR = 1.334 and 1.303 separately). Conclusions Malignancy history may have no marked effect on the severity and prognosis of COVID-19. Lymphopenia, NLR and CRP levels could be regarded as indicators to determine severe cases, and predict progression and survival.